Literature DB >> 2157317

Antigenic cross-reaction between a varicella-zoster virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid protein.

A Vafai1, Z Wroblewska, L Graf.   

Abstract

Human sera from varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1) seropositive individuals contain antibody to a 155-kilodalton (155 kDa) viral protein. In this study, we show that monoclonal antibodies (mAb10.1 and mAb1A1.4) prepared against VZV and HSV-1 proteins, respectively, reacted with nuclear antigens and recognized a 155 kDa protein in the infected cells. Immunoprecipitation of whole virions and viral nucleocapsids with these mAbs showed that the 155 kDa protein is located in VZV and HSV-1 nucleocapsids. In addition, immunofluorescence and cross-reaction experiments revealed the antigenic cross-reactivity between the VZV and HSV-1 155 kDa nucleocapsid proteins. To map the coding region of the VZV 155 kDa protein, a truncated DNA fragment from the predicted open reading frame 40 was cloned into an in vitro transcription vector (pGEM). The RNA transcribed from the inserted DNA was translated in vitro and immunoprecipitated with mAb10.1. The reactivity of the in vitro translation products with mAb10.1 indicated that the 155 kDa nucleocapsid protein is encoded by VZV gene 40. These findings demonstrated that the VZV 155 kDa nucleocapsid protein encoded by gene 40 induces humoral response which cross-reacts with both VZV and HSV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157317     DOI: 10.1016/0168-1702(90)90006-w

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  4 in total

1.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

2.  Humoral and cellular CMV responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donors.

Authors:  Nina Loeth; Kristian Assing; Hans O Madsen; Lars Vindeløv; Soren Buus; Anette Stryhn
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

3.  Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.

Authors:  Bernhard Banas; Carsten A Böger; Gerhard Lückhoff; Bernd Krüger; Sascha Barabas; Julia Batzilla; Mathias Schemmerer; Josef Köstler; Hanna Bendfeldt; Anne Rascle; Ralf Wagner; Ludwig Deml; Joachim Leicht; Bernhard K Krämer
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

4.  Varicella-zoster virus-associated meningitis, encephalitis, and myelitis with sporadic skin blisters: A case report.

Authors:  Ken Takami; Tsuneaki Kenzaka; Ayako Kumabe; Megumi Fukuzawa; Yoko Eto; Shun Nakata; Katsuhiro Shinohara; Kazunori Endo
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.